相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Review
Biochemistry & Molecular Biology
Jessica L. Justinussen et al.
Summary: Excessive daytime sleepiness is a complex symptom characterized by strong urge to sleep during daytime and accompanied by attention deficits, anxiety, and lower cognitive performance. Treatment strategies for EDS have focused on decreasing sleepiness, but less attention has been given to the quality of wakefulness. This review discusses the potential effects of HCRTR2 agonists on attention and anxiety in treating EDS, suggesting that these compounds may improve both the quantity and quality of wakefulness in narcolepsy.
TRENDS IN MOLECULAR MEDICINE
(2023)
Article
Clinical Neurology
Emmanuel Mignot et al.
Summary: This study aimed to investigate the safety, pharmacokinetics, and pharmacodynamics of danavorexton, a small-molecule orexin-2 receptor agonist, in adults with idiopathic hypersomnia (IH). The results showed that a single infusion of danavorexton improved excessive daytime sleepiness in patients with IH without serious adverse events, indicating that orexin-2 receptor agonists are promising treatments for IH.
Article
Medicine, General & Internal
Y. Dauvilliers et al.
Summary: This study found that TAK-994 had a good therapeutic effect in patients with narcolepsy type 1, improving sleepiness and cataplexy symptoms, but it was associated with hepatotoxic effects.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Clinical Neurology
Richard K. Bogan et al.
Summary: This study aimed to investigate the safety and effects of danavorexton on residual EDS in patients with OSA. The results showed that danavorexton can improve subjective and objective measures of EDS in patients with OSA despite adequate CPAP use.
Review
Clinical Neurology
Fabio Pizza et al.
Summary: The orexins, or hypocretins, are neuropeptides produced by neurons in the lateral hypothalamus and play a role in regulating sleep, wakefulness, and other functions. Destruction of orexin neurons leads to narcolepsy in humans, and impairments in orexin signaling cause narcoleptic-like symptoms in animals. The discovery of orexins has revolutionized sleep research and holds promise for therapeutic applications in various fields.
JOURNAL OF SLEEP RESEARCH
(2022)
Article
Multidisciplinary Sciences
Rebecca Evans et al.
Summary: Narcolepsy is a sleep disorder that can be classified into type 1 and type 2. The drug danavorexton shows promising results in treating narcolepsy by targeting both orexin 1 and orexin 2 receptors.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Review
Clinical Neurology
Kiran Maski et al.
Summary: This systematic review provides evidence on the treatment of central disorders of hypersomnolence in adults and children, focusing on prescription medications with FDA approval and nonpharmacologic interventions. The review identified 144 studies meeting inclusion criteria, with 108 providing data suitable for statistical analyses. The task force presented evidence on various interventions and assessed the quality of evidence, balance of benefits and harms, patient values and preferences, and resource use considerations.
JOURNAL OF CLINICAL SLEEP MEDICINE
(2021)
Article
Clinical Neurology
Lois E. Krahn et al.
Summary: This article updates the American Academy of Sleep Medicine protocols for the administration of the Multiple Sleep Latency Test and the Maintenance of Wakefulness Test. Although no evidence-based changes to the protocols were warranted, the task force made several changes based on consensus. These changes included guidance on patient preparation, medication and substance use, sleep before testing, test scheduling, optimum test conditions, and documentation.
JOURNAL OF CLINICAL SLEEP MEDICINE
(2021)
Article
Neurosciences
JT Willie et al.
